Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Ester Del Signore
Observed names:
Del Signore, E.,
E. Del Signore,
ESTER DEL SIGNORE,
Ester del Signore
Institution:
European Institute of Oncology
Observed institutions:
University of Milan,
Policlinico Umberto I,
Azienda Ospedaliera San Camillo-Forlanini,
European Institute of Oncology,
Sapienza University of Rome
ORCID:
0000-0002-5286-7285
Observed ORCID:
0000-0002-5286-7285
OpenAlex ID:
A5073021827
Bone and brain metastasis in lung cancer: recent advances in therapeutic strategies
2014
·
Chiara D’Antonio
, Antonio Passaro
, et al.
·
Therapeutic Advances in Medical Oncology
·
243
Advancements in fourth-generation EGFR TKIs in EGFR-mutant NSCLC: Bridging biological insights and therapeutic development
2024
·
Carla Corvaja
, Antonio Passaro
, et al.
·
Cancer Treatment Reviews
·
104
PDF
Clinical features affecting survival in metastatic NSCLC treated with immunotherapy: A critical review of published data
2020
·
Antonio Passaro
, Ilaria Attili
, et al.
·
Cancer Treatment Reviews
·
84
New Generations of Tyrosine Kinase Inhibitors in Treating NSCLC with Oncogene Addiction: Strengths and Limitations
2023
·
Ilaria Attili
, Carla Corvaja
, et al.
·
Cancers
·
58
PDF
Immune checkpoint inhibitors in EGFR-mutant non-small cell lung cancer: A systematic review
2023
·
Ilaria Attili
, Antonio Passaro
, et al.
·
Cancer Treatment Reviews
·
47
Gr-MDSC-linked asset as a potential immune biomarker in pretreated NSCLC receiving nivolumab as second-line therapy
2019
·
A. Passaro
, P. Mancuso
, et al.
·
Clinical & Translational Oncology
·
44
Palonosetron plus 3-day aprepitant and dexamethasone to prevent nausea and vomiting in patients receiving highly emetogenic chemotherapy
2010
·
Flavia Longo
, Giovanni Mansueto
, et al.
·
Supportive Care in Cancer
·
42
Surgery for small cell lung cancer: When and how
2020
·
Monica Casiraghi
, Giulia Sedda
, et al.
·
Lung Cancer
·
40
Management of Nonhematologic Toxicities Associated With Different EGFR-TKIs in Advanced NSCLC: A Comparison Analysis
2014
·
Antonio Passaro
, Massimo Di Maio
, et al.
·
Clinical Lung Cancer
·
36
MET in Non-Small-Cell Lung Cancer (NSCLC): Cross ‘a Long and Winding Road’ Looking for a Target
2023
·
Gianluca Spitaleri
, Pamela Trillo Aliaga
, et al.
·
Cancers
·
29
PDF
HER2 in Non-Small Cell Lung Cancer (NSCLC): Evolution of the Therapeutic Landscape and Emerging Drugs—A Long Way to the Top
2025
·
Pamela Trillo Aliaga
, Gianluca Spitaleri
, et al.
·
Molecules
·
27
PDF
Fears and Perception of the Impact of COVID-19 on Patients With Lung Cancer: A Mono-Institutional Survey
2020
·
Chiara Catania
, Gianluca Spitaleri
, et al.
·
Frontiers in Oncology
·
27
PDF
Results of Multilevel Containment Measures to Better Protect Lung Cancer Patients From COVID-19: The IEO Model
2020
·
Filippo de Marinis
, Ilaria Attili
, et al.
·
Frontiers in Oncology
·
24
PDF
Efficacy of Anti-PD1/PD-L1 Therapy (IO) in KRAS Mutant Non-small Cell Lung Cancer Patients: A Retrospective Analysis
2019
·
LETIZIA GIANONCELLI
, GIANLUCA SPITALERI
, et al.
·
Anticancer Research
·
24
PDF
The role of multimodal treatment in patients with advanced lung neuroendocrine tumors
2017
·
Nicola Fazio
, Antonio Ungaro
, et al.
·
Journal of Thoracic Disease
·
22
PDF
Dealing with KRAS G12C inhibition in non-small cell lung cancer (NSCLC) – biology, clinical results and future directions
2025
·
Ilaria Attili
, Carla Corvaja
, et al.
·
Cancer Treatment Reviews
·
20
Post-Progression Analysis of EGFR-Mutant NSCLC Following Osimertinib Therapy in Real-World Settings
2024
·
Ilaria Attili
, Carla Corvaja
, et al.
·
Cancers
·
20
The new era of immune checkpoint inhibition and target therapy in early-stage non-small cell lung cancer. A review of the literature
2021
·
Chiara Catania
, Bharathi Muthusamy
, et al.
·
Clinical Lung Cancer
·
20
Atezolizumab Plus Carboplatin and Etoposide in Patients with Untreated Extensive-Stage Small-Cell Lung Cancer: Interim Results of the MAURIS Phase IIIb Trial
2023
·
Emilio Bria
, Floriana Morgillo
, et al.
·
The Oncologist
·
19
PDF
Management of MET-Driven Resistance to Osimertinib in EGFR-Mutant Non-Small Cell Lung Cancer
2025
·
Panagiotis Agisilaos Angelopoulos
, Antonio Passaro
, et al.
·
Genes
·
18
PDF
Co-Occurring Driver Genomic Alterations in Advanced Non-Small-Cell Lung Cancer (NSCLC): A Retrospective Analysis
2024
·
Ilaria Attili
, Riccardo Asnaghi
, et al.
·
Journal of Clinical Medicine
·
18
PDF
Management of Non-Metastatic Non-Small Cell Lung Cancer (NSCLC) with Driver Gene Alterations: An Evolving Scenario
2024
·
Valeria Fuorivia
, Ilaria Attili
, et al.
·
Current Oncology
·
17
PDF
Comparison of real-world data (RWD) analysis on efficacy and post-progression outcomes with pembrolizumab plus chemo vs chemo alone in metastatic non-squamous non-small cell lung cancer with PD-L1 < 50%
2022
·
Ilaria Attili
, Carmine Valenza
, et al.
·
Frontiers in Oncology
·
16
Sustained Improvement in the Management of Patients with Non-Small-Cell Lung Cancer (NSCLC) Harboring ALK Translocation: Where Are We Running?
2023
·
Gianluca Spitaleri
, Pamela Trillo Aliaga
, et al.
·
Current Oncology
·
15
PDF
Efficacy and Tolerability of long-acting Octreotide in the Treatment of Thymic Tumors: Results of a Pilot Trial
2011
·
Flavia Longo
, Lucilla De Filippis
, et al.
·
American Journal of Clinical Oncology
·
14
Show more works
View as search
Works count:
68
Citation count:
1,145
H-index:
19
I10-index:
28
Year
Topic
Type